Clinical characteristics of patients with the SAMD9/SAMD9L gene defects
-
Published:2022-08-29
Issue:3
Volume:21
Page:126-135
-
ISSN:2414-9314
-
Container-title:Pediatric Hematology/Oncology and Immunopathology
-
language:
-
Short-container-title:Voprosy gematologii/onkologii i immunopatologii v pediatrii
Author:
Avedova A. Ya.1ORCID, Mersiyanova I. V.1ORCID, Pavlova A. V.1ORCID, Sultanova E. R.1ORCID, Petrova U. N.1ORCID, Balashov D. N.1ORCID, Shelikhova L. N.1ORCID, Raykina E. V.1ORCID, Pershin D. E.1ORCID, Pshonkin A. V.1ORCID, Fedorova D. V.1ORCID
Affiliation:
1. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Abstract
Conditions associated with defects in the SAMD9/SAMD9L genes represent a relatively new group of diseases characterized by a diverse range of clinical manifestations: from multisystem disorders such as MIRAGE syndrome to isolated hematological manifestations. A previous history of infectious diseases in patients with SAMD9/SAMD9L gene defects before the onset of hematological manifestations is in most cases associated with the defects of the immune system. Gain- or change-of-function germline mutations in the SAMD9/SAMD9L genes are the most common predisposition factors for pediatric myelodysplastic syndrome (MDS) with monosomy 7. However, SAMD9/SAMD9L patients with cytogenetic rearrangements but without any signs or symptoms of MDS can have spontaneous remission due to various compensatory cellular mechanisms. The presence of primary immunodeficiency and a predisposition to MDS at an early age requires a more detailed approach to this group of patients and early determination of indications for allogeneic hematopoietic stem cell transplantation. The patients’ parents gave their consent to the use of their child’s data, including photographs, for research purposes and in publications.
Publisher
Fund Doctors, Innovations, Science for Children
Subject
Oncology,Hematology,Immunology,Immunology and Allergy,Pediatrics, Perinatology and Child Health
Reference23 articles.
1. Sahoo S, Pastor V, Goodings Ch, Voss R, Kozyra E, Szvetnik A et al. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nat Med. 2021 Oct;27(10):1806-1817. 2. Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. J Clin Immunol. 2020 Jan;40(1):66-81. doi: 10.1007/s10875-020-00758-x. 3. Narumi S, Amano N, Ishii T, Katsumata N, Muroya K, Adachi M et al. SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nature Genetics, 2016 Jul;48(7):792-7. doi: 10.1038/ng. 3569. 4. Buonocore F, Kühnen P, Suntharalingham J.P, Ignacio Del Valle, Digweed M, Stachelscheid H et al. Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humans. J Clin Invest. 2017 May 1;127(5):1700-1713. doi: 10.1172/JCI91913. 5. Nagamachi A, Matsui H, Asou H, Ozaki Y, Aki D, Kanai A et al. Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7. Cancer Cell 2013; 24: 305–317.
|
|